Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Metabolism of [14C] BMS-986195 in Healthy Males
NCT03245515Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2017
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of branebrutinib in rheumatoid arthritis (RA), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration up to 16 days, Time to attain maximum observed plasma concentration up to 16 days and 7 more. Started Aug 2017; status: completed.
02
Drugs
branebrutinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03245515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03245515.